Ajanta Pharma Limited

NSEI:AJANTPHARM Rapporto sulle azioni

Cap. di mercato: ₹321.6b

Ajanta Pharma Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Yogesh Agrawal

Amministratore delegato

₹216.0m

Compenso totale

Percentuale dello stipendio del CEO57.23%
Mandato del CEO17.4yrs
Proprietà del CEO14.5%
Durata media del managementNessun dato
Durata media del Consiglio di amministrazione6.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

Mar 29
If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Feb 20
What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 02
Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Dec 15
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
author-image

Branded Generics Growth And Global Expansion Will Accelerate Earnings And Market Share

Ajanta Pharma's strong performance in Branded Generics and effective cash management strategy indicate robust future revenue and margin improvements.

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Sep 10
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Aug 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04
Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

Aug 01
Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Jun 01
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

May 05
Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

Apr 05
Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Feb 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Dec 23
Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Aug 26
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Feb 07
These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Oct 24
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Aug 25
Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

Jul 19
Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Apr 28
A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Mar 14
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Feb 06
I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Dec 13
Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Oct 31
Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Sep 22
Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Sep 08
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Aug 26
Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Jul 07
Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Jun 14
Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

May 15
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 10
Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 11
Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Feb 24
Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Yogesh Agrawal rispetto agli utili di Ajanta Pharma?
DataCompenso totaleStipendioGuadagni aziendali
Mar 31 2025n/an/a

₹9b

Dec 31 2024n/an/a

₹9b

Sep 30 2024n/an/a

₹9b

Jun 30 2024n/an/a

₹9b

Mar 31 2024₹216m₹124m

₹8b

Dec 31 2023n/an/a

₹7b

Sep 30 2023n/an/a

₹7b

Jun 30 2023n/an/a

₹6b

Mar 31 2023₹156m₹112m

₹6b

Dec 31 2022n/an/a

₹6b

Sep 30 2022n/an/a

₹7b

Jun 30 2022n/an/a

₹7b

Mar 31 2022₹163m₹94m

₹7b

Dec 31 2021n/an/a

₹7b

Sep 30 2021n/an/a

₹7b

Jun 30 2021n/an/a

₹7b

Mar 31 2021₹128m₹75m

₹7b

Dec 31 2020n/an/a

₹6b

Sep 30 2020n/an/a

₹6b

Jun 30 2020n/an/a

₹5b

Mar 31 2020₹107m₹66m

₹5b

Dec 31 2019n/an/a

₹4b

Sep 30 2019n/an/a

₹4b

Jun 30 2019n/an/a

₹4b

Mar 31 2019₹99m₹61m

₹4b

Compensazione vs Mercato: La retribuzione totale di Yogesh ($USD 2.53M ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 570.28K ).

Compensazione vs guadagni: La retribuzione di Yogesh è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Yogesh Agrawal (52 yo)

17.4yrs
Mandato
₹215,960,000
Compensazione

Mr. Yogesh Mannalal Agrawal, M.B.A, has been Managing Director at Ajanta Pharma Ltd. since December 14, 2007. Mr. Agrawal is handling global business of Ajanta Pharma Ltd.He has handled various aspects of...

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Yogesh Agrawal
MD & Executive Director25.1yrs₹215.96m14.48%
₹ 46.5b
Rajesh Agrawal
Joint MD & Director12.1yrs₹215.96m27.48%
₹ 88.4b
Madhusudan Agrawal
Executive Vice Chairman of the Board27.4yrs₹42.04mNessun dato
Ramesh Jhawar
Director of Ajanta Pharma USA Inc.no data₹25.50mNessun dato
Mannalal Agrawal
Chairman of the Board45.4yrs₹777.00kNessun dato
David Rasquinha
Independent Non-Executive Director1yrNessun datoNessun dato
Medha Joshi
Independent Non-Executive Director1yrNessun datoNessun dato
Sam Gioskos
Director of Ajanta Pharma Philippines Inc.no dataNessun datoNessun dato
Suttian Deerpaul
Director of Ajanta Pharma (Mauritius) Ltd.no dataNessun datoNessun dato
Vinayak Muzumdar
Director of Ajanta Pharma (Mauritius) Ltd.no dataNessun datoNessun dato
Rajesh Dalal
Independent Non-Executive Director1yrNessun datoNessun dato
Simi Thapar
Independent Non-Executive Director1yrNessun datoNessun dato
6.5yrs
Durata media
68yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AJANTPHARM sono considerati esperti (durata media dell'incarico 6.5 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/05/23 05:49
Prezzo dell'azione a fine giornata2025/05/23 00:00
Guadagni2025/03/31
Guadagni annuali2025/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Ajanta Pharma Limited è coperta da 25 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Rashmi Sancheti ShettyAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
null nullAsian Markets Securities Private Limited